In short
Anhydrous Docetaxel, a potent chemotherapy drug, is being investigated in several clinical trials for its potential to treat various types of cancer. These trials aim to evaluate the efficacy and safety of Anhydrous Docetaxel, either alone or in combination with other treatments, for patients with advanced or metastatic cancers, including breast, gastric, esophageal, and Ewing sarcoma. The ongoing research seeks to improve treatment outcomes and quality of life for cancer patients.
What is ANHYDROUS DOCETAXEL?
ANHYDROUS DOCETAXEL is a powerful medication used in cancer treatment. It belongs to a class of drugs known as antineoplastics, which are substances that help prevent or inhibit the growth of cancer cells. The term "anhydrous" means that the medication does not contain water, which can affect its stability and effectiveness.
ANHYDROUS DOCETAXEL is also known simply as DOCETAXEL. Both names refer to the same active substance, with ANHYDROUS DOCETAXEL being a specific formulation. This medication is typically administered as a solution for infusion, which means it is given directly into the bloodstream through a vein (intravenously).
What Conditions Does ANHYDROUS DOCETAXEL Treat?
ANHYDROUS DOCETAXEL is used to treat various types of cancer. Based on the clinical trials information provided, it is being studied for use in the following conditions:
- HER2-Positive, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer: This is a specific type of breast cancer that has either spread to nearby tissues (locally advanced) or to other parts of the body (metastatic). HER2-positive means the cancer cells have a protein called HER2 on their surface, which promotes cancer growth. PIK3CA mutation refers to a specific genetic change in the cancer cells.
- Advanced or Metastatic Stomach and Esophagus Cancer: This refers to cancers of the stomach or the tube connecting the throat to the stomach (esophagus) that have spread to nearby tissues or other parts of the body.
- Recurrent and Primary Refractory Ewing Sarcoma: This is a rare type of cancer that occurs in bones or in the soft tissue around the bones. "Recurrent" means the cancer has come back after treatment, while "primary refractory" means the cancer did not respond to initial treatment.
How is ANHYDROUS DOCETAXEL Used?
ANHYDROUS DOCETAXEL is typically administered as an intravenous infusion, which means it is given directly into a vein. The dosage and frequency of treatment can vary depending on the specific condition being treated and the individual patient's needs. Here are some examples from the clinical trials:
- For breast cancer treatment, it may be given at a dose of 50 mg per square meter of body surface area (mg/m2) every 3 weeks.
- In the treatment of stomach and esophagus cancer, it might be used at a dose of 50 mg/m2 as part of a combination therapy regimen.
- For Ewing Sarcoma, the dosage being studied is 80 mg/m2, with treatments potentially lasting up to 18 weeks.
It's important to note that these dosages are from clinical trials and may not reflect the final approved dosages. Always follow your doctor's instructions regarding dosage and administration.
Current Clinical Trials
ANHYDROUS DOCETAXEL is currently being studied in several clinical trials:
- Breast Cancer Study: This trial is comparing the effectiveness of a combination therapy including ANHYDROUS DOCETAXEL with other treatments for HER2-positive, PIK3CA mutated advanced breast cancer.
- Stomach and Esophagus Cancer Study: This trial is evaluating ANHYDROUS DOCETAXEL as part of a combination therapy (called TFOX) for advanced or metastatic stomach and esophagus cancer.
- Ewing Sarcoma Study: This trial is comparing different chemotherapy regimens, including one with ANHYDROUS DOCETAXEL, for the treatment of recurrent and primary refractory Ewing Sarcoma.
Potential Side Effects and Precautions
While the clinical trial information doesn't provide a comprehensive list of side effects, it's important to be aware that as a powerful cancer medication, ANHYDROUS DOCETAXEL can cause significant side effects. Some potential side effects and precautions mentioned in the trial information include:
- Blood Cell Count Changes: The medication may affect your blood cell counts. Your doctor will monitor these closely.
- Liver Function: Your liver function may be affected and will be monitored during treatment.
- Heart Function: Your heart function may be monitored before and during treatment.
- Fertility and Pregnancy: This medication may affect fertility. If you're of childbearing age, you'll need to use effective contraception during treatment and for some time afterwards. It should not be used during pregnancy or while breastfeeding.
Always discuss potential side effects and precautions with your healthcare provider before starting treatment with ANHYDROUS DOCETAXEL.